Send to

Choose Destination

See 1 citation found using an alternative search:

J Intern Med. 2000 May;247(5):521-34.

Multidrug resistance in haematological malignancies.

Author information

University Hospital Rotterdam - Dijkzigt, Department of Hematology, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. sonneveld@haed.azr.nL


The development of refractory disease in acute myeloid or lymphoblastic leukaemias (AML, ALL) and multiple myeloma (MM) is frequently associated with the expression of one or several multidrug resistance (MDR) genes. MDR1, MRP1 and LRP have been identified as important adverse prognostic factors in AML, T-ALL and MM. Recently, it has become possible to reverse clinical multidrug resistance by blocking P-glycoprotein-mediated drug efflux. The potential relevance of these reversal agents of MDR and potential new approaches to treat refractory disease are discussed.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center